Company news

Femasys Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

March 27, 2025

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

March 19, 2025

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

March 18, 2025

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

March 13, 2025

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

February 25, 2025

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

February 10, 2025

Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

February 3, 2025

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

January 29, 2025

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

January 15, 2025

Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed

December 2, 2024

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

November 25, 2024

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

November 11, 2024

Femasys to Exhibit at the Annual AAGL 2024 Global Conference

November 6, 2024

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

October 31, 2024

Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed

October 29, 2024

Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program

October 9, 2024

Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

October 7, 2024

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

October 1, 2024

Femasys Announces Infertility Clinic Customers from Coast to Coast

September 17, 2024

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

September 10, 2024

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

September 8, 2024

Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting

September 4, 2024

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

August 28, 2024

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

August 26, 2024

Femasys Inc. at August 20th Virtual Investor Summit Microcap Event

August 18, 2024

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

August 7, 2024

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

June 26, 2024

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

June 19, 2024

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 16, 2024

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council

May 15, 2024

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 8, 2024

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

May 6, 2024

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives

April 17, 2024

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

March 27, 2024

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

March 20, 2024

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

March 19, 2024

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

March 12, 2024

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

March 5, 2024

Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

February 27, 2024

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

February 5, 2024

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

January 25, 2024

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

January 22, 2024

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

December 14, 2023

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

November 29, 2023

Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch

November 27, 2023

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

November 14, 2023

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update

November 13, 2023

Femasys Inc. EU MDR Final Audit Successfully Completed

October 25, 2023

Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons

October 24, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 14 decks. Every deck is listed under its year.